Kura Oncology KURA Business Segments
| Q1 '26 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Development Services For Monotherapy | $7.2M— | —— | —— | —— | —— | |
| Development Services In Combination With Other Therapies | $5.3M— | —— | —— | —— | —— | |
| License And Collaboration Revenue | $12.5M-11.4% | $14.11M+4.7% | $13.47M0.0% | $13.47M0.0% | $13.47M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
